A major Chinese pharmaceutical company has called on the National Institutes of Health (NIH) in Islamabad to collaborate in conducting clinical trials of its newly developed inactivated vaccine against Covid-19 in Pakistan.
Developing countries, often lacking a pharmaceutical industry to develop, test, and manufacture vaccines, and the money to buy them elsewhere, have been forced to join allied or international groups trying to produce vaccines for poor countries. , to look for supplies.
Read Also : DRAP Approved first local covid testing kit
"China has not been a major vaccine manufacturer worldwide. It is imperative to test its COVID-19 vaccines beyond its borders as the number of coronavirus cases in China has declined and it is more difficult to find the required population diversity," the report said. .
The publication reported that state-owned China National Pharmaceutical Group, commonly known as Sinopharm, has partnered with Karachi University's International Center for Chemical and Biological Sciences to conduct the trials in Pakistan.
The race for vaccines against the coronavirus has intensified in recent weeks and Western countries have also brought their vaccines to the final testing phase. COVID-19 vaccines are currently being developed by Oxford University and US-based Moderna Inc.
Although Pakistan lifted the coronavirus shutdown a few days ago, government officials have called on the masses to implement COVID-19 SOPs and measures to prevent another wave of the virus.
